We are live on
!
Find out more
SMV
Sofinnova Management VIII Portfolio holdings
AUM
$183M
1-Year Est. Return
4.18%
This Fund
S&P 500
This Quarter
Est. Return
+18.06%
1 Year Est. Return
+4.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
-$14.4M
(-8.1%)
Cap. Flow
-$36.7M
Cap. Flow
% of AUM
-22.37%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
–
Reduced
2
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NCNA
NuCana
NCNA
|
+$11.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$27.3M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$16.1M |
| 3 |
INNL
Innocoll Holdings plc Ordinary Shares
INNL
|
+$4.79M |
| 4 |
SYBX
Synlogic
SYBX
|
+$205 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ONCE
1
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $42.9M | 26.16% |
481,270
-211,858
| -31% | -$16.1M |
|
2
Aclaris Therapeutics
ACRS
$842M
| $39.7M | 24.23% |
1,539,480
| – | – |
|
|
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $30.5M | 18.61% |
3,749,623
| – | – |
|
4
Natera
NTRA
$44.8B
| $20M | 12.18% |
1,550,280
| – | – |
|
|
NCNA
5
NuCana
NCNA
$6.66M
| $12.2M | 7.47% |
+133
| New | +$11.5M |
|
|
SYBX
6
DELISTED
Synlogic
SYBX
| $8.08M | 4.93% |
28,331
-1
| -0% | -$205 |
|
|
CYTO
7
DELISTED
Altamira Therapeutics Ltd
CYTO
| $6.41M | 3.91% |
98
| – | – |
|
8
Ocugen
OCGN
$451M
| $4.11M | 2.51% |
34,617
| – | – |
|
|
ARAV
9
DELISTED
Aravive, Inc. Common Stock
ARAV
| – | – |
-260,543
| Closed | -$27.3M |
|
|
INNL
10
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
| – | – |
-2,103,173
| Closed | -$4.79M |
|
Similar funds
BIC
CCM
YP
EI
W
IA
WI
TCM
Sofinnova Management VIII's Q3 2017 Portfolio in Review
As of Q3 2017, Sofinnova Management VIII held 10 positions worth $164M, down 8.1% from $178M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sofinnova Management VIII withdrew a net $36.7M in Q3 2017, closing 2 positions and reducing 2 holdings. Its most notable exit was Aravive, Inc. Common Stock, an estimated $27.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Sofinnova Management VIII opened a new position in NuCana worth $12.2M.
- Sofinnova Management VIII's largest Q3 2017 buy was NuCana: 133 shares worth $12.2M.
- Sofinnova Management VIII's biggest Q3 2017 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $16.1M.
- Sofinnova Management VIII fully exited Aravive, Inc. Common Stock in Q3 2017, selling an estimated $27.3M.
- Sofinnova Management VIII's ten largest holdings make up 100% of its $164M portfolio in Q3 2017.
- Sofinnova Management VIII opened 1 new position and closed 2 in Q3 2017.
- Sofinnova Management VIII's portfolio value fell 8.1% quarter-over-quarter to $164M.
Based on Sofinnova Management VIII's 13F filing for Q3 2017, filed 11 Oct 2017.